PART I Overview We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering...
Q2 FY2026 — expected 2026-09-10
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | MXCT | discussed_in_filing Cybersecurity | |
| topic_mention | MXCT | discussed_in_filing Trusted Computing | |
| topic_mention | MXCT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | MXCT | discussed_in_filing Capital Expenditure | |
| topic_mention | MXCT | discussed_in_filing Supply Chain | |
| topic_mention | MXCT | discussed_in_filing Regulation | |
| topic_mention | MXCT | discussed_in_filing Healthcare & Bio | |
| topic_mention | MXCT | discussed_in_filing Platform & Ecosystem | |
| topic_mention | MXCT | discussed_in_filing Sovereign & Government | |
| topic_mention | MXCT | discussed_in_filing Cybersecurity | |
| topic_mention | MXCT | discussed_in_filing Trusted Computing | |
| topic_mention | MXCT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | MXCT | discussed_in_filing Capital Expenditure | |
| topic_mention | MXCT | discussed_in_filing Supply Chain | |
| topic_mention | MXCT | discussed_in_filing Regulation | |
| topic_mention | MXCT | discussed_in_filing Healthcare & Bio | |
| topic_mention | MXCT | discussed_in_filing Platform & Ecosystem | |
| topic_mention | MXCT | discussed_in_filing Sovereign & Government | |
| topic_mention | MXCT | discussed_in_filing Cybersecurity | |
| topic_mention | MXCT | discussed_in_filing Trusted Computing |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001104659-26-034557 | EDGAR | 74K words |
| 2025-03-11 | 2024-12-31 | 0001558370-25-002721 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0001558370-24-003001 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0001558370-23-003911 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001558370-22-004081 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001104659-25-111396 | EDGAR | 23K words |
| 2025-08-06 | 2025-06-30 | 0001558370-25-010554 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001558370-25-007005 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014662 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011120 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007085 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018314 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014306 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009167 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017204 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013091 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001558370-22-007869 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001104659-26-036201 | EDGAR | 1K words |
| 2026-03-24 | 0001104659-26-033867 | EDGAR | — |
| 2026-03-20 | 0001104659-26-032761 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002901 | EDGAR | — |
| 2025-11-12 | 0001104659-25-110375 | EDGAR | — |
| 2025-11-05 | 0001104659-25-107118 | EDGAR | — |
| 2025-09-22 | 0001104659-25-092162 | EDGAR | — |
| 2025-08-11 | 0001558370-25-011056 | EDGAR | — |
| 2025-08-06 | 0001558370-25-010523 | EDGAR | — |
| 2025-06-25 | 0001558370-25-008856 | EDGAR | — |
75 total filings indexed. 48 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001287098 |
| Ticker | MXCT |
| Exchange | Nasdaq |
| SIC | 8731: Services-Commercial Physical & Biological Research |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report